Ocuphire Pharma Inc
NASDAQ:OCUP 1:40:28 PM EDT
Products
Ocuphire Pharma Inc - Issuance Extends Nyxol's U.S. Patent Protection From 2034 Into 2039 For RM Indication
Published: 08/03/2022 12:51 GMT
Ocuphire Pharma Inc (OCUP) - Ocuphire Extends U.S. Patent Protection for Late-stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years Into 2039 With New Patent Issuance.
Ocuphire Pharma Inc - Issuance Extends Nyxol's U.S. Patent Protection From 2034 Into 2039 for Rm Indication.
Ocuphire Pharma Inc - Growing Patent Estate Eligible for FDA Orange Book Listing.
Ocuphire Pharma Inc - on Track to File NDA for Nyxol in First Indication Rm in Late 2022.
Ocuphire Pharma Inc - Potential Second Half 2023 Approval As Only Eye Dilation Reversal Drop.
Ocuphire Pharma Inc - If Approved, Nyxol Could Be Launched in Second Half of 2023.
Ocuphire Pharma Inc - Issuance Extends Nyxol's U.S. Patent Protection From 2034 Into 2039 for Rm Indication.
Ocuphire Pharma Inc - Growing Patent Estate Eligible for FDA Orange Book Listing.
Ocuphire Pharma Inc - on Track to File NDA for Nyxol in First Indication Rm in Late 2022.
Ocuphire Pharma Inc - Potential Second Half 2023 Approval As Only Eye Dilation Reversal Drop.
Ocuphire Pharma Inc - If Approved, Nyxol Could Be Launched in Second Half of 2023.